Welcome to our dedicated page for Bioventus SEC filings (Ticker: BVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bioventus Inc. filings document the formal disclosures of a Nasdaq-listed medical device company with Class A common stock registered under the Exchange Act. Recent Form 8-K reports furnish operating results and financial condition updates, including quarterly and annual earnings releases for the company’s active-healing product portfolio.
The company’s regulatory filings also cover proxy governance for annual stockholder meetings, board composition matters, emerging growth company status, credit arrangements entered into by Bioventus LLC and its subsidiaries, and product regulatory events such as FDA 510(k) clearance for TalisMann and StimTrial within the Peripheral Nerve Stimulation portfolio.
Bioventus Inc. (BVS) reported an insider transaction on a Form 4. A director sold 17,701 shares of Class A common stock on 11/07/2025 at a weighted average price of $7.4151. The filing notes multiple trades executed between $7.36 and $7.43.
Following the sale, the reporting person beneficially owns 56,997 shares, held directly. The transaction is coded “S,” indicating an open‑market or private sale. The filing was made by one reporting person.
Bioventus Inc. (BVS) reported Q3 2025 results. Net sales were $138.651 million, essentially flat year over year. Operating income improved to $11.252 million from $3.647 million, and net income attributable to Bioventus was $3.155 million (diluted EPS $0.05) versus a loss of $5.165 million (diluted EPS $(0.08)) a year ago.
For the first nine months, net sales were $410.187 million and net income attributable to Bioventus was $7.977 million (diluted EPS $0.12) versus a loss of $35.737 million (diluted EPS $(0.56)) last year. Cash from operating activities rose to $36.705 million; cash ended at $42.164 million.
The company refinanced its debt on July 31, 2025 with a new $300 million term loan and a $100 million revolver maturing in 2030. As of quarter end, $25 million was drawn on the revolver, with $75 million available, and Bioventus was in compliance with covenants. It entered interest rate swaps covering $150 million notional at a weighted average fixed rate of 3.60%, recognized as a $785 thousand loss in AOCI. The company paid $19.771 million of Bioness contingent consideration and recorded no further Bioness obligations. Bioventus also recorded an immaterial revision to 2024 equity-based compensation, adjusting prior-period figures.
Bioventus Inc. (BVS) reported results for the three and nine months ended September 27, 2025. The company announced these financial results via a press release furnished as Exhibit 99.1 to a Form 8-K.
The information in Item 2.02, including Exhibit 99.1, is furnished, not filed, and is not subject to Section 18 liabilities, nor incorporated by reference unless expressly stated. The filing also lists Exhibit 104, the cover page Inline XBRL data.
Nantahala Capital Management, LLC and two principals report beneficial ownership of 5,280,842 shares of Bioventus Inc. Class A common stock, representing 7.96% of the outstanding class as of June 30, 2025. The filing states the shares are held by funds and separately managed accounts under Nantahala's control and that Nantahala and its managing members, Wilmot B. Harkey and Daniel Mack, share voting and dispositive power over these shares but have no sole voting or dispositive power. The filing is submitted on a Schedule 13G/A indicating the holdings are in the ordinary course of business and not intended to influence control of the issuer. The document includes the issuer address and signatures dated August 14, 2025.
Bioventus Inc. (BVS) entered into a Credit Agreement dated July 31, 2025, establishing a $100 million revolving credit facility and a $300 million first lien term loan A facility, and drew $30 million under the revolver on the Closing Date.
Key terms:
- Total facilities: $400 million ($100M revolver, $300M term loan)
- Maturity: July 31, 2030
- Interest: Term SOFR plus initial margin 2.50% (margin thereafter adjusted quarterly by consolidated total net leverage bands)
- Amortization: Term loan amortizes 5% of original principal annually; balance due at maturity
- Fees: Revolver commitment fee 0.30% (stepdown 0.10% if leverage <2.50x); revolver includes $7.5M letter of credit and $7.5M swingline sub-facilities
- Covenants: secured by substantially all assets; maximum consolidated total net leverage 4.00x (through Q4 2025) then 3.50x thereafter (temporary 0.50x election for certain acquisitions); consolidated interest coverage >=2.50x starting Q3 2025
Bioventus Inc. (BVS) filed a Form 8-K to report that on 30 Jul 2025 the U.S. FDA granted 510(k) clearance for two Peripheral Nerve Stimulation (PNS) devices, TalisMann™ and StimTrial™. The decision permits immediate U.S. marketing without additional clinical trials, expanding Bioventus’ portfolio beyond orthobiologics and bone-healing systems.
No revenue, margin or guidance figures were disclosed, yet management signals a new addressable market in neuromodulation. Clearance could diversify revenue streams and leverage the company’s existing sales infrastructure; however, launch timing, pricing, reimbursement and market-share expectations remain unspecified.
- Item reported: 8.01 – Other Events
- Regulatory milestone: FDA 510(k) clearance
- Products affected: TalisMann & StimTrial PNS devices
- Potential impact: accelerates entry into U.S. PNS market, incremental growth driver